Rigel Pharmaceuticals, Inc.
NASDAQ: RIGL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Raul R. Rodriguez
- Employees
- 174
- Headquarters
- South San Francisco, United States
- IPO year
- 2000
- Market cap
- $676.3M
- Website
- https://www.rigel.com
Loading RIGL…
Loading profile data…Frequently asked questions about RIGL
What does Rigel Pharmaceuticals, Inc. (RIGL) do?
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-inte...
Where does RIGL trade?
Rigel Pharmaceuticals, Inc. (RIGL) trades on the NASDAQ.
What sector is RIGL in?
Rigel Pharmaceuticals, Inc. (RIGL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Rigel Pharmaceuticals, Inc.?
Raul R. Rodriguez is the chief executive officer of Rigel Pharmaceuticals, Inc. (RIGL).
Where is Rigel Pharmaceuticals, Inc. headquartered?
Rigel Pharmaceuticals, Inc. is headquartered in United States.
Does RIGL pay a dividend?
Rigel Pharmaceuticals, Inc. (RIGL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RIGL go public?
Rigel Pharmaceuticals, Inc. (RIGL) completed its initial public offering in 2000.